Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Summit Therapeutics recruits for US leg of PhaseOut study

Wednesday, November 16, 2016 7:54
% of readers think this story is Fact. Add your two cents.

Summit Therapeutics PLC (LON:SUMM NASDAQ:SMMT) has enrolled its first patients at trial sites in the US into PhaseOut DMD.

PhaseOut is a Phase 2 proof of concept clinical trial of its utrophin modulator ezutromid in patients with DMD.

Dosing is expected to follow for US patients within 28 days.

The PhaseOut trial is already underway in the UK.

John Jefferies, at Cincinnati Children’s Hospital and the US trial’s coordinating investigator said: “Ezutromid has shown great promise in preclinical testing as a universal treatment that has the potential to slow or stop disease progression in all patients with DMD, regardless of their underlying dystrophin gene mutation.” 

DMD (Duchenne Muscular Dystrophy)  is caused by different mutations in the dystrophin gene that result in patients being unable to produce the protein, which is essential for maintaining healthy muscle function. 

Ezutromid is designed to increase the levels of another, similar, protein call utrophin to compensate from the lack dystrophin. The system is called utrophin modulation.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.